chartexchange

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

GlobeNewswire Inc. | Nov 6, 2026 4:01 PM EST

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET, to review initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis being presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.

Read original article